MR Tissue 4D Workflow Job Aid

MR Tissue 4D Workflow Job Aid syngo.via MR The MR Tissue 4D is used in Dynamic Contrast imaging to characterize the properties of the contrast agent passage through the tissue. Parametric maps are calculated based on a Volume of Interest (VOI) and permit the user to generate findings on specific regions of interest using Tissue 4D tools. 1. From the Patient Browser, load the appropriate data set into the MR Tissue 4D Workflow:  If the examination has been correctly mapped, double‐click to load  If manual mapping is required, right‐click the examination and select Assign Workflow > MR Tissue 4D 2. Motion Correction Step is used to verify the automatic alignment of the dynamic data set to a defined reference volume. a. Select > Toggle Images Icon to toggle between the motion corrected and non‐motion corrected series Motion Comection Blanding 100% b. Blended slider > move the slider to the required time point > select the confirm icon to confirm new reference point Motion Correction Blending 100% Note: Can exclude time points by moving the slider to the required time point; select the Exclude Phase icon or Exclude Rest All icon which excludes all time points after the selected time point. 3. Alignment Step is used to verify the automatic alignment of the pre‐contrast and morphology series to the dynamic series a. Aligning morphological and dynamic data i. Check automatic alignment ii. If necessary, select another Morphology data set from the list Published by Siemens Healthcare GmbH © Siemens Healthcare GmbH, 2018 SIEMENS Master Template: EFF Date 22 Aug 17 | HOOD/HILS HOOD05162002647849 Healthineers Jobaid: Effective Date: 08/14/2019 | HOOD05162003027209 MR Tissue 4D Workflow Job Aid Effective Date: 08/14/2019 | HOOD05162003027209 iii. Use the Blending slider to evaluate visually the quality of the selected morphological data with the dynamic volume iv. If necessary, you can toggle between the aligned and non‐aligned data by se‐ lecting this Toggle Images icon. You can distinguish aligned and non‐aligned images by the series name which is displayed in the image text. Alignment Pre-contrast To Dynamic Flo Angle 15 Blending 100% b. Aligning pre‐contrast and dynamic data i. Check automatic alignment ii. If required select a Flip Angle or measured T1 map from the list iii. Use the Blending slider to evaluate visually the quality of the selected pre‐ contrast data with the dynamic volume iv. If necessary, you can toggle between the aligned and non‐aligned data by se‐ lecting this Toggle Images icon. You can distinguish aligned and non‐aligned images by the series name which is displayed in the image text. Alignment Pre-contrast To Dynamic Flip Angle 15 Blending 100% 4. Processing Step is used to verify or modify the result of the pharmacokinetic modeling with‐ in a specific volume of interest or to define a new volume of interest and to start a new eval‐ uation. You may choose between two models: Tofts model or Qualitative model. Qualitative model is used to calculate the contrast medium concentration. Tofts model is used to evaluate the quantitative blood flow of the tissue. a. In the image segment, check the predefined VOI. b. If necessary, choose the VOI tool from the upper right corner menu to draw a new VOI Published by Siemens Healthcare GmbH © Siemens Healthcare GmbH, 2018 Page 2 of 6 MR Tissue 4D Workflow Job Aid Effective Date: 08/14/2019 | HOOD05162003027209 AH Distance Line ROI Circle IR Tissuc4D Poland MAC Marier IT 00 D13 Ch ATOW CURRENT 72014 Angle Abs tra p2 dyn CM 15 0 MOCO vol Sphere 01 005 VOI Freshand STUDY D 1nnnn 1357 VOI Sphere 3.18:55PM 1010 MMAna MR Segmentation RFA SCH F TIR 6 3 TE 2.4 EW 1900 TP MPR : PÌ MAGNINAVAIL/MO.COMMIND NORM 156-256| EHI AL/SATI T HF1 4 NE1. Blasticaly Aligned Mythance c. In the Case Navigator, select the pharmacokinetic Model (i.e. Tofts or Qualitative) from the list. Model Tofte Contrast Agent Multihance Protocol Pixelwise T1 10.62 sec i. If you selected the Tofts model from the list, the AIF Selection list is displayed ii. AIF Selection: choose Fast, Intermediate or Slow that provides applicable in‐ formation about the concentration of the contrast agent in the blood. Processing Model Tofts AIF Intermediate Contrast Agent Fast Intermediate Protocol Slow Published by Siemens Healthcare GmbH © Siemens Healthcare GmbH, 2018 Page 3 of 6 MR Tissue 4D Workflow Job Aid Effective Date: 08/14/2019 | HOOD05162003027209 iii. Note: Select the Settings icon if you want to adjust the settings for the selected Contrast Agent and the Protocol. 1. The MR Tissue 4D Processing Settings dialog box opens. Adjust the settings for the Contrast Agent and the Protocol. Select OK. MR Tissue4D Processing Settings ? X Contrast Agent Magnevist Field Strength 1.5T Gadovist Prohance Relaxivity 6.7 Vmmol's Multihance Molarity 0.5 mmol/ml Dotarem Omniscan Dose 0.1 mmol/kg Optimark Volume 11 m Protocol . Qualitative . Tofts Protocol Type Pixelwise T1 Threshold 20 OK Cancel iv. Select the Arrival Time icon to display the arrival time bar in the upper right segment. Processing Model Tolls AIF Intermediate Contrast Agent Multihance Protocol Pixelwise T1 10.02 sec 1. Manipulate the time bar to adjust the arrival time. Published by Siemens Healthcare GmbH © Siemens Healthcare GmbH, 2018 Page 4 of 6 MR Tissue 4D Workflow Job Aid Effective Date: 08/14/2019 | HOOD05162003027209 v. Select the Calculate Maps icon to start calculation of the parametric maps Processing Model Tons AIF Intermediate Contrast Agent Mumthance Protocol Pixelwise T1 10.02 sec 5. The Reading Step is used to evaluate the created maps and to create findings. a. Go through images and mark relevant areas using the tools from the upper right cor‐ ner menu or use the icons in the Reading step. The result for the marked area is dis‐ played below the graph. For each drawn ROI or VOI, a finding is automatically creat‐ ed and listed in the Findings Navigator. b. If required, select another parametric map from the lower left corner menu. Reading CSV Piel Lens E por Io Freehand Sphere 6. The Viewing Step is used for viewing images. MR Tissue4D + MR Tissue4D Analysis Viewing Published by Siemens Healthcare GmbH © Siemens Healthcare GmbH, 2018 Page 5 of 6 MR Tissue 4D Workflow Job Aid Effective Date: 08/14/2019 | HOOD05162003027209 Please note that the learning material is for training purposes only! For the proper use of the software or hardware, please always use the Operator Manual or Instructions for Use (herein‐ after collectively “Operator Manual”) issued by Siemens Healthineers. This material is to be used as training material only and shall by no means substitute the Operator Manual. Any material used in this training will not be updated on a regular basis and does not necessarily reflect the latest version of the software and hardware available at the time of the training. The Operator's Manual shall be used as your main reference, in particular for relevant safety information like warnings and cautions. Note: Some functions shown in this material are optional and might not be part of your system. Certain products, product related claims or functionalities (hereinafter collectively “Functionality”) may not (yet) be commercially available in your country. Due to regulatory requirements, the future availability of said Functionalities in any specific country is not guaranteed. Please contact your local Siemens Healthineers sales representative for the most current information. The reproduction, transmission or distribution of this training or its contents is not permitted without express written authority. Offenders will be liable for damages. All names and data of patients, parameters and configuration dependent designations are fictional and examples only. All rights, including rights created by patent grant or registration of a utility model or design, are reserved. Copyright © Siemens Healthcare GmbH 2018 ………………………………………………………… Siemens Healthineers Headquarters Siemens Healthcare GmbH Henkestr. 127 91052 Erlangen, Germany Telephone: +49 9131 84‐0 siemens.com/healthineers Published by Siemens Healthcare GmbH © Siemens Healthcare GmbH, 2018 Page 6 of 6